-
Foreword
The complete sequencing of the human genome in conjunction with increasingly sophisticated molecular biological techniques have dramatically increased our understanding of the genetic events leading to carcinogenesis. Today, new cancer-related genetic changes seem to be described almost daily and the full potential of genetic profiling of individuals for cancer risk has yet to be realized. Although such profiling will represent an enormous advance, the full therapeutic implications of this technology are only beginning to be understood. For the surgeon, these advances have the potential to not only alter the role of surgery in traditional treatment paradigms but also offer the possibility of prophylactic intervention in at-risk individuals before cancer development. Although this latter ap...
-
Citing clinical evidence, coalition urges U.S. panel to approve CT colonography for screening
A growing body of evidence supports the use of CT colonography for colon cancer screening and a U.S. panel should reverse its decision to not endorse the procedure, according to the CT Colonography Coalition. (Source: Diagnostic Imaging)
-
Dr Oz colon polyps raises question of "spontaneous disease" without cause
(NaturalNews) Dr Oz was recently found to have a precancerous colon polyp which was surgically removed. Following this experience, he appears to be surprised and confused about the origin of the condition, and he credits colonoscopy screening with saving his life.Dr Oz even seems to think he has a perfect health record, saying, "I have done everything right. I don't have any family history, and yet I'm high risk now." His personal physician, meanwhile, is implying that even though Dr Oz's "healthy" diet was perfect, it wasn't enough to prevent colon polyps, and therefore you might get them too. (And therefore everybody should get screened...)Dr Jonathan Lapook, went on to say "...no matter what you do, you can't totally eliminate your risk of developing this disease, which is expected to s...
-
Cetuximab: Development of resistance in metastatic colon cancer: case report
(Source: Reactions)
-
Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort
Objective To examine the hypothesis that risk of oesophageal, but not of gastric or colorectal, cancer is increased in users of oral bisphosphonates.
Design Nested case-control analysis within a... (Source: BMJ Online First)
-
Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1
Abstract Camptothecin (CPT) and Nutlin-3 caused apoptosis by increasing p53 protein and its activation in intestinal epithelial cells
(IEC-6). We studied the effectiveness of these inducers on apoptosis in human colon cancer cells (Caco2) lacking p53 expression.
CPT failed to activate caspase-3 and cause apoptosis in these cells. The absence of p53 expression, higher basal Bcl-xL and
lower Bax proteins prevented CPT-induced apoptosis. However, the Mdm2 antagonist Nutlin-3 induced apoptosis in a dose dependent
manner by activating caspases-9 and -3. Nutlin-3 prevented the activation of AKT via PTEN-mediated inhibition of the PI3K
pathway. Nutlin-3 increased the phosphorylation of retinoblastoma protein causing E2F1 release leading to induction of Siva-1.
Nutlin-3-mediated d...
-
Inhibition of metastasis of syngeneic murine melanoma in vivo and vasculogenesis in vitro by monoclonal antibody C11C1 targeted to domain 5 of high molecular weight kininogen
Abstract Metastasis of malignant tumors is a major cause of morbidity and mortality. Inhibition of tumor growth in distant organs is
of clinical importance. We have demonstrated that C11C1, a murine monoclonal antibody to the light chain region of high molecular
weight kininogen (HK), reduces growth of murine multiple myeloma in normal mice and human colon cancer in nude mice. C11C1
inhibits angiogenesis by reducing tumor microvascular density by blocking binding of HK to endothelial cells. We now evaluate
the anti-metastatic effect of C11C1 on C57BL/6 mouse lung metastatic model using B16F10 melanoma cells. The tail veins of
mice were injected with 0.5 × 106 cells of melanoma B16F10. One group received C11C1 and the other received saline (control) intraperitonea...
-
Colon cancer: UF researcher receives $1.5 million grfant to study origin of colon cancer
Emina Huang, M.D., an associate professor of surgery in the University of Florida's College of Medicine, has received a $1.52 million grant from the National Institutes of Health to fund her research into the origins of colon cancer.
The five-year... (Source: OrlandoSentinel: Medical Research)
-
Human papillomavirus and colorectal cancer: evidences and pitfalls of published literature
Conclusions HPV has been detected in the majority of reported series, but published literature lacks in definitive data regarding standard
methods of investigation and stratification of groups and population. These data encourage further studies with the aim to
investigate the presence of the virus in larger series, its possible role in oncogenesis, the integration in host genome,
the expression of viral oncoproteins, the mutations in HPV positive cancers and routes of colon infection (hematologic/lymphatic
spreading or perineal diffusion).
Content Type Journal ArticleDOI 10.1007/s00384-010-1049-8Authors
Laura Lorenzon, II Faculty of Medicine and Surgery, University of Rome “La Sapienza”, St. Andrea Hospital, Via di Grottarossa, 1035-39, 00189 Rome, ItalyMario...
-
Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human solid tumor models
Conclusions The application of CrA for the treatment of PBE likely involves its activity as an antiangiogenic agent, which may be one
possible mechanism to explain its observed preclinical antitumor activity. That activity, as well as its ability to provide
an enhanced therapeutic outcome when given in conjunction with BEV in the absence of increased toxicity, supports the use
of CrA clinically as other than a replacement therapy for dexamethasone in PBE.
Content Type Journal ArticleDOI 10.1007/s00280-010-1437-3Authors
Idoia Gamez, Celtic Pharmaceutical Development Services America, Inc, 663 Fifth Ave, 7th Floor, New York, 10022 NY USARobert P. Ryan, Celtic Pharmaceutical Development Services America, Inc, 663 Fifth Ave, 7th Floor, New York, 10022 NY USALakesha D. ...
|